150
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Synthesis and antibacterial and antifungal activities of novel thiochroman-4-one derivatives incorporating oxime ether and 1,3,4-oxadiazole thioether moieties

, , &
Pages 1063-1068 | Received 06 Jan 2022, Accepted 19 Mar 2022, Published online: 11 May 2022
 

Abstract

In this study, 18 novel thiochroman-4-one derivatives incorporating oxime ether and 1,3,4-oxadiazole thioether moieties were synthesized and their structures analyzed by 1H NMR, 13C NMR, and HRMS. Their in vitro antibacterial activities against Xanthomonas oryzae pv. oryzae (Xoo) and Xanthomonas axonopodis pv. citri (Xac) as well as antifungal activities against Botrytis cinerea (B. cinerea), Verticillium dahliae (V. dahliae), and Fusarium oxysporum (F. oxysporum) were determined. Bioassay results showed that compound 6-chloro-2-(5-(methylthio)-1,3,4-oxadiazol-2-yl)thiochroman-4-one O-methyl oxime (7a) was found to be the most active against Xoo and Xac, with the median effective concentration values (EC50) of 17 and 28 μg/mL, respectively, which were even better than those of Bismerthiazol and Thiodiazole copper. Meanwhile, compound 2-(5-(ethylthio)-1,3,4-oxadiazol-2-yl)-6-methylthiochroman-4-one O-methyl oxime (7j) showed better in vitro antifungal activity against B. cinerea, with the inhibition rate of 79%, than that of Carbendazim. As far as we know, this paper is the first report on the synthesis and antibacterial and antifungal activities of this series of novel thiochroman-4-one derivatives incorporating oxime ether and 1,3,4-oxadiazole thioether moieties.

Graphical Abstract

Disclosure statement

The authors declare no conflict of interest.

Additional information

Funding

This research was funded by Kaili University Doctoral Program, grant number BS201811; Science and Technology Foundation of Guizhou Province, grant number ZK[2021]137 and [2020]1Y130; National Natural Science Foundation of China, grant number 32102267.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.